Study Compares HSCT Outcomes in Rare T-Cell Lymphoma Subtype

By Melissa Badamo, Hemant Murthy, MD - Last Updated: July 18, 2024

Hemant Murthy, MD, an Associate Professor of Medicine at the Mayo Clinic in Florida, discusses his study on hematopoietic stem cell transplantation (HSCT) outcomes in patients with hepatosplenic T-cell lymphoma.

Advertisement

The study found no significant differences in overall survival or progression-free survival between allogeneic HSCT and autologous HSCT.

“[HSCT] is an effective treatment that can prolong survival, and patients should be referred as early as possible to transplant centers for evaluation,” Dr. Murthy said.

While autologous transplant can be considered for older patients, he recommends reserving it for patients who cannot receive allogeneic transplant and ensuring that patients reach complete remission prior to autologous transplant.

More data are needed to validate these findings, but Dr. Murthy hopes this study makes clear the need to optimize patient outcomes through clinical trials and improved therapies.

“These studies are crucial to helping clinicians with management and transplant outcomes of rare diseases such as hepatosplenic T-cell lymphoma,” he concluded.

Advertisement
Advertisement
Advertisement
Editorial Board